A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti PD-1) INCAGN02385 (Anti LAG-3) and INCAGN02390 (Anti TIM-3) in Participants With Select Advanced Malignancies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Select Advanced Malignancies
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) For Phase 1: Participants with locally advanced or metastatic solid tumors for which a PD-1 inhibitor is indicated (locally advanced disease must not be amenable to resection with curative intent) that have failed a PD-1/PD-L1 inhibitor therapy. 2) For Phase 2: Participants with histologically confirmed recurrent melanoma who relapsed during therapy with anti–PD-1 given as adjuvant therapy. 3) Participants must have fresh biopsy available after completing adjuvant therapy or be willing and able to safely undergo pretreatment tumor biopsies (core or excisional).

You may not be eligible for this study if the following are true:

  • 1) Known hypersensitivity or severe reaction to any component of the study drugs or formulation components for INCMGA00012 or INCAGN02385 or INCAGN02390 of colony-stimulating factors within 14 days before study Day 1.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.